TECH Bio-Techne Corp

The global cell therapy manufacturing market is projected to reach USD 15.14 billion by 2032, growing at a CAGR of 15.1% from USD 5.65 billion in 2025. Coherent Market Insights' report provides detailed analysis including segmentation by therapy type, technology, manufacturing purpose, and application, alongside profiles of key companies. The study aims to help decision-makers navigate the evolving market and capitalize on upcoming opportunities in this rapidly innovating sector.

This article provides a comprehensive history of Bio-Techne Corp (TECH) stock price and market capitalization data. It includes current stock performance, 52-week highs and lows, and historical yearly data for open, high, low, close, and return. The piece also offers a brief overview of recent news concerning other major stocks.

Voya Investment Management LLC significantly reduced its stake in Bio-Techne Corp (NASDAQ:TECH) by 71.9% in Q3, selling 324,328 shares and retaining 126,453 shares valued at approximately $7.04 million. Institutional ownership of Bio-Techne remains very high at 98.95%, with other major institutional investors like Select Equity Group and Norges Bank holding substantial positions. Bio-Techne currently trades near $58.71, has a market cap of $9.15 billion, and pays a quarterly dividend of $0.08, while analysts have a consensus "Moderate Buy" rating with a price target of $71.00.

BTIG has reaffirmed its Buy rating and $7 price target for MDxHealth (NASDAQ:MDXH), anticipating accelerated revenue growth and improved EBITDA margins in 2026. The firm highlights MDxHealth's strong position in prostate diagnostics, particularly following the successful integration of its ExoDx acquisition, distinguishing it as an attractive small-cap growth and value stock. Despite a recent earnings miss, BTIG maintains confidence, noting the company's valuation is below peers and analyst consensus is a Strong Buy.

Assenagon Asset Management S.A. has acquired a new position of 49,446 shares, valued at $2.75 million, in Bio-Techne Corp (NASDAQ:TECH) during the third quarter. Other institutional investors have also adjusted their holdings in the biotechnology company, which reported Q3 EPS in line with estimates but revenue slightly below expectations. Bio-Techne pays a quarterly dividend of $0.08, has a P/E of about 120.9, and carries a consensus "Moderate Buy" rating with a target price near $71 from analysts.

Bio-Techne Corporation announced that its President and CEO, Kim Kelderman, will present at the 2026 J.P. Morgan Healthcare Conference on January 13, 2026. The presentation will be webcast live on Bio-Techne's investor relations website. Bio-Techne is a global life sciences company providing tools and reagents for research and diagnostics.